Zobrazeno 1 - 10
of 20
pro vyhledávání: '"E. Yu. Solovyeva"'
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 11, Iss 1, Pp 72-78 (2019)
Objective: to assess changes in the vascular platelet component of hemostasis in patients in different recovery periods of ischemic stroke (IS).Patients and methods. The investigation enrolled 73 patients with prior IS. According to the remoteness of
Externí odkaz:
https://doaj.org/article/0dcc218eab3640ffbd6f7ca8c9135bee
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 8, Iss 2, Pp 17-23 (2016)
Objective: to evaluate the efficacy of Tanakan® (EGB761®) used in young and middle-aged patients with mixed cognitive impairments (CI) and emotional diseases.Patients and methods. An open-label observational study of the efficacy of Tanakan® was c
Externí odkaz:
https://doaj.org/article/fb031154210946999d9b18b72b432ee1
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 9, Iss 6, Pp 74-82 (2010)
Aim. To study the lipid-lowering effectiveness, as well as the effects on inflammatory markers and vascular wall function, of ezetimibe as monotherapy and in combination with initial doses of original statins (simvastatin, atorvastatin, and rosuvasta
Externí odkaz:
https://doaj.org/article/7486f6539fd04d2eb025942954437df4
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 8, Iss 6, Pp 98-110 (2009)
The increased level of low-density lipoprotein cholesterol (LDL-CH) is one of the risk factors (RFs) of coronary heart disease and atherosclerosis. Statins, with their vast evidence base on mortality reduction, are the principal medications in athero
Externí odkaz:
https://doaj.org/article/6836815ef96543199b2c96ad5b35161c
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 5, Iss 5, Pp 5-13 (2006)
Aim. To assess coronary heart disease (CHD) and its risk factors (RF) prevalence, as well as their interaction in patients with heterozygotic form of familial hypercholesterolemia (FHCH). Material and methods. The analysis included 200 patients aged
Externí odkaz:
https://doaj.org/article/046bea86efb94849822c759ed73a24de
Autor:
I. V. Kukes, V. G. Lim, K. A. Ivantsov, E. Yu. Solovyeva, L. P. Sokolova, I. R. Gilmutdinova, P. B. Glagovskiy, M. S. Ptitsyn
Publikováno v:
Meditsinskiy sovet = Medical Council. :57-64
Introduction. The material presents the results of the study of the effectiveness of the drug Ethylmethylhydroxypyridine malate in patients with long COVID, based on the dynamics of clinical manifestations and metabolomic parameters responsible for t
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 121(8. Vyp. 2)
Atherothrombotic stroke is the one of the most common subtypes of ischemic cerebral circulatory disorders, the cause of which is atherosclerosis of the major arteries of the brain or their branches. The results of recent studies have shown that the a
Autor:
A.V. Romanenko, E. Yu. Solovyeva
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 121(3)
Cardioembolic stroke (CS) is the one of the most severe and requiring dynamic monitoring among the all subtypes of ischemic stroke. Patients with CS require joint treatment with cardiologists. CS is characterized by a greater severity of neurological
Autor:
A. V. Chekanov, V. A. Shchelkonogov, G. M. Sorokoumova, O. A. Baranova, A. M. Sinebryukhova, K. I. Farakhova, A. N. Karneev, E. Yu. Solovyeva
Publikováno v:
Neuroscience and Behavioral Physiology. 49:738-742
Objectives. To assess changes in the phospholipid composition of blood plasma in patients with chronic cerebrovascular disease using the neuroprotectors 2-ethyl-6-methyl-3-hydroxypyridine succinate (Neurox) and citocoline (Neipilept), which are natur
Publikováno v:
Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 8, Iss 2, Pp 17-23 (2016)
Objective: to evaluate the efficacy of Tanakan® (EGB761®) used in young and middle-aged patients with mixed cognitive impairments (CI) and emotional diseases. Patients and methods. An open-label observational study of the efficacy of Tanakan® was